This presentation has been prepared by Orchid Chemicals and Pharmaceuticals Limited ("Orchid" or the "Company") solely for your information and for your use and may not be taken away, distributed, reproduced, or redistributed or passed on, directly or indirectly, to any other person (whether within or outside your organization or firm) or published in whole or in part, for any purpose by recipients directly or indirectly to any other person. By accessing this presentation, you are agreeing to be bound by the trailing restrictions and to maintain absolute confidentiality regarding the information disclosed in these materials.

This presentation does not constitute an offer or invitation to purchase or subscribe for any securities of the Company by any person in any jurisdiction, including India and the United States. No part of it should form the basis of or be relied upon in connection with any investment decision or any contract or commitment to purchase or subscribe for any securities. Securities may not be offered or sold in the United States absent registration or an exemption from registration. This presentation is not intended to be a prospectus (as defined under the Companies Act, 1956) or offer document under the Securities and Exchange Board of India (Issue of Capital and Disclosure Requirements) Regulations, 2009 as amended.

No representation or warranty, express or implied, is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or opinions contained in this presentation. Such information and opinions are in all events not current after the date of this presentation. Certain statements made in this presentation may not be based on historical information or facts and may be "forward looking statements" based on the currently held beliefs and assumptions of the management of the Company, which are expressed in good faith and in their opinion reasonable, including those relating to the Company’s general business plans and strategy, its future financial condition and growth prospects and future developments in its industry and its competitive and regulatory environment.

This presentation may contain statements that constitute forward-looking statements. Forward-looking statements involve known and unknown risks, uncertainties and other factors, which may cause the actual results, financial condition, performance or achievements of the Company or industry results to differ materially from the results, financial condition, performance or achievements expressed or implied by such forward-looking statements, including future changes or developments in the Company's business, its competitive environment and political, economic, legal and social conditions. Further, past performance is not necessarily indicative of future results. Given these risks, uncertainties and other factors, viewers of this presentation are cautioned not to place undue reliance on these forward-looking statements. The Company disclaims any obligation to update these forward-looking statements to reflect future events or developments.

This presentation is for general information purposes only, without regard to any specific objectives, financial situations or informational needs of any particular person. The Company may alter, modify or otherwise change in any manner the content of this presentation, without obligation to notify any person of such change or changes. This presentation may not be copied or disseminated in any manner.
One of the leading Indian Specialty companies with strong capabilities in oral and injectable antibiotic APIs and niche generics

**Business Overview**

- **Promoted by K. Raghavendra Rao**, who has been conferred the Padma Shri in 2011 by the Government of India

- **Products and Development**
  - Manufactures APIs for Cephalosporins (Injectables and Oral), Penicillins (Injectables) and Carbapenems (Injectables)
  - Sells API products with limited competition to global partners under long term supply agreements
  - Manufactures oral FDFs for Cephalosporins and NPNCs across multiple therapeutic areas
  - Expanding oral FDF franchise on the back of strong R&D capabilities and track record of regulatory filings including first-to-files (FTFs)

- **Manufacturing Capability**
  - Two API manufacturing sites (Chennai and Aurangabad), three formulation sites (Chennai)
  - Manufacturing facilities are in compliance with cGMP, cGLP, ISO and OHSAS guidelines; approved by global regulatory authorities such as US FDA, UK MHRA, EDQM, PMDA, DMA, MCC and TGA

- **Geographical Presence**
  - Sales spread across regulated (US, Europe, Japan) and emerging markets (CIS, China, Middle East, India, etc.) through own front end presence and alliances
  - Key partners include Hospira, Alvogen and a leading Japanese innovator

- **Financial Snapshot**
  - FY12 Revenues of US$ 373.8 mm and EBITDA of US$ 81.1 mm

- **Shareholding as of February 2013**
  - Total no. of shares: 70.4 mm
  - Promoters hold 32.4%, FIIs 5.5%, DIIs 4.5%, Individuals 29.5%, Bodies Corporate 26.3% and others 1.8%

**Consolidated Financials**

<table>
<thead>
<tr>
<th></th>
<th>FY10</th>
<th>FY11</th>
<th>FY12</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Income</strong></td>
<td>265.7</td>
<td>350.9</td>
<td>373.8</td>
</tr>
<tr>
<td><strong>Y-o-Y Growth</strong></td>
<td>4.3%</td>
<td>32.1%</td>
<td>6.5%</td>
</tr>
<tr>
<td><strong>EBITDA</strong></td>
<td>(30.7)</td>
<td>78.8</td>
<td>81.1</td>
</tr>
<tr>
<td><strong>EBITDA Margin</strong></td>
<td>(11.5%)</td>
<td>22.4%</td>
<td>21.7%</td>
</tr>
<tr>
<td><strong>Profit After Tax (PAT)</strong></td>
<td>66.6</td>
<td>30.7</td>
<td>19.1</td>
</tr>
<tr>
<td><strong>PAT Margin</strong></td>
<td>25.0%</td>
<td>8.7%</td>
<td>5.1%</td>
</tr>
<tr>
<td><strong>Net Worth</strong></td>
<td>184.2</td>
<td>210.1</td>
<td>249.7</td>
</tr>
<tr>
<td><strong>Total Loans</strong></td>
<td>370.6</td>
<td>428.7</td>
<td>394.7</td>
</tr>
<tr>
<td><strong>Cash and Bank Balances</strong></td>
<td>65.8</td>
<td>43.7</td>
<td>35.7</td>
</tr>
</tbody>
</table>

**Revenue Breakup (FY2012)**

**Revenue Break-up by Product**

- FDF: Finished Dosage Forms
- API: Active Pharmaceuticals Ingredients

**Revenue Break-up by Geography**

- Regulated Markets: 63%
- Emerging Markets: 37%

**Note:**

(1) All financials are for fiscal year (FY) ended March 31. Fx used: US$1 = Rs 50.88
(2) EBITDA figures include other operating income and exclude other income and other non-recurring income.
(3) PAT as reported in consolidated financials.
(4) FY10 PAT includes US$ 207 mm on account of sale of assets. FY12 PAT is impacted by higher interest charges, currency fluctuations and loss due to plant shutdown. 
(5) Total Debt in FY11 includes US$ 117 mm of FCCB redeemed in February 2012, and redemption premium of US$ 50mm.
(6) FDF: Finished Dosage Forms. API: Active Pharmaceuticals Ingredients.
Global generics market is expected to grow to US$ 135-150bn in 2015 owing to the impending patent cliff, increasing penetration of generics and higher consumption.

The generics injectables market is expected to witness higher growth.

Orchid is well positioned to leverage this opportunity given its diversified presence and end to end capabilities.

In addition, Orchid’s oral FDFs pipeline, addressing the large oral opportunity is expected to be a key growth driver.

Injectables, a specialized and niche area, is a lucrative market segment given small number of competitors and hence high profitability margins; USA and EU account for ~75% of the global injectables market.

Global Market Size

US$ 20bn generic injectables
US$ 143bn global injectables
US$ 773bn global pharmaceuticals market

Geographical Breakdown of Generic Injectables

US 50%
EU 24%
EM 20%
ORM 6%

ORM = Other Regulated Markets

Upcoming Injectables Patent Expiries Provide Substantial Opportunity

2011 $1.5
2012E $3.1
2013E $4.1
2014E $2.6
2015E $1.4

Source: Street Research.
## Business Highlights

**A High End Specialty Player**
- Product portfolio of niche molecules involving complex chemistry, multi-step manufacturing, dedicated infrastructure and a challenging patent environment are entry barriers for other pharmaceutical players.

**Integrated Capabilities**
- Strong end-to-end capabilities with presence across the entire value chain of APIs and formulations backed by strong manufacturing and regulatory capabilities along with front-end presence across markets.

**Diversified Geographic Presence**
- Orchid has global presence in over 70 countries through partnerships and own front end presence spread across both the regulated and emerging markets.

**Strategy in Place for Next Growth Phase**
- Strengthen position as a Specialty high end generics player with best in class regulatory and development capabilities.
- Long term supply contracts and new product approvals to be the key growth drivers.

**Strong Operating Performance**
- Good growth in revenues and margins in FY12; growth going forward to be driven by development of new product segments and supplies to key regulated markets / customers.

**Strong Manufacturing Infrastructure**
- Five state of the art API and formulations manufacturing facilities with approvals from leading agencies providing global competitive edge.

**NCE Pipeline**
- NCE Pipeline provides significant upsides through licensing arrangements and partnerships.

**Excellent Regulatory & R&D Capabilities**
- Strong track record of regulatory filings and large product pipeline with total addressable market size of US$ 75-80 bn, total of 73 filings in the US and EU with 53 approvals in place.
A High End Specialty Player

Key Business Segments

Orchid Chemicals & Pharmaceuticals Limited

- **Cephalosporin**
  - API for Injectables
  - API for Orals
  - Orals (FDFs)

- **Penicillin**
  - API for Injectables

- **Carbapenems**
  - API for Injectables

- **NPNC (Non-penicillin and Non-cephalosporin)**
  - API for Orals
  - Orals (FDFs)

Product Offerings

- Specializes in niche APIs for injectables and orals that have limited competition due to high entry barriers enabling the Company to earn strong revenue and profitability
  - Difficult-to-make molecules involving complex chemistry, multi-step manufacturing, dedicated infrastructure and a challenging patent environment
- APIs sold under long-term supply agreement to Hospira (for Carbapenems, Tazo-Pip and ADD-Vantage) generating high EBITDA margins
  - Tazo-Pip is a niche antibiotic with few ANDAs pending approval; Add-Vantage is Hospira’s patented drug delivery system, under protection till 2016
- Large generics pipeline of NPNCs and Cephalosporins across multiple therapeutic areas with significant revenue potential
Integrated Capabilities

Orchid is present across the value chain

End-to-end development capabilities delivers higher margins

- Strong R&D capability with a team of 130 plus with several doctoral and post-doctoral scientists
- Expertise in manufacturing difficult-to-make APIs with high entry barriers leading to high margins
- Track record of FDF filings in the regulated markets (73 filings, 53 approvals)
- Orchid partnerships ensure a steady stream of revenue
  - Long-term API supply agreement with Hospira for products with limited competition. In addition to supplies to Hospira, the Company has the right to supply APIs to one more generic player in each regulated market
  - Tie-up with a leading European generics player to supply carbapenem APIs to the European market
  - Long-term agreement with a Japanese pharmaceutical company for supply of a Cephalosporin API, enhancing revenues
  - Tie-up with Alvogen for distribution of eight specific FDF products
- Acquisition of US-based Karalex Pharma has created own front end, which can be leveraged to monetize the FDF pipeline
## Strong Manufacturing Infrastructure

### Capacity expansion based on order-book of top clients and strong FDF pipeline

<table>
<thead>
<tr>
<th>Facility</th>
<th>Products</th>
<th>Approvals</th>
<th>Markets</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>API Facility</strong>&lt;br&gt;Aurangabad, Maharashtra</td>
<td>Penicillins, Sterile Carbapenems, Non-Penicillin, Non-cephalosporins (NPNC)</td>
<td>UK MHRA, US FDA, OHSAS 18001: 1999, Danish Medicines Agency, EU-GMP, WHO-GMP Audit</td>
<td>Emerging and regulated markets</td>
</tr>
<tr>
<td><strong>Formulation Facilities</strong>&lt;sup&gt;(1)&lt;/sup&gt;&lt;br&gt;Irungattukottai (Chennai), Tamil Nadu</td>
<td>Oral dosage form complex with multi-therapeutic facilities, Oral cephalosporin formulations, NPNC (non antibiotic) dosage forms</td>
<td>US FDA, UK MHRA</td>
<td>Regulated Markets - US and Europe</td>
</tr>
<tr>
<td><strong>Research Laboratories</strong></td>
<td>NDD, NDDS, CRAMS and generic research</td>
<td>GLP accredited by National GLP Authority of India, aligned with OECD Principles</td>
<td>--</td>
</tr>
</tbody>
</table>

---

Source: Company reports

Note: 1) All three formulation facilities are part of Chennai campus
Excellent Regulatory & R&D Capabilities

Overview of Regulatory Capabilities

- Strong track record of regulatory filings
  - An aggregate of 73 filings across NPNC\(^1\) and Cephalosporins in regulated markets (43 ANDAs in the US and 30 filings in EU)
  - 53 approvals in place (31 in US, 22 in EU)
- 8 products in the First-to-file pipeline in the US
- Additional pipeline of 125 NPNC, Cephalosporin, Penems & Penicillin products across US, EU and other geographies
- Total addressable market size of US$ 75-80bn

First To File Pipeline

<table>
<thead>
<tr>
<th>Products</th>
<th>TA</th>
<th>Brand Name</th>
<th>Peak sales (US$ mm)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Desloratadine Tabs</td>
<td>Anti-allergics</td>
<td>Clarinex</td>
<td>275</td>
</tr>
<tr>
<td>Desloratadine ODT</td>
<td>Anti-allergics</td>
<td>Clarinex</td>
<td>20</td>
</tr>
<tr>
<td>Ibandronate Sodium Tabs</td>
<td>Osteoporosis</td>
<td>Boniva</td>
<td>1,200</td>
</tr>
<tr>
<td>Duloxetine DR Cap-Pellets</td>
<td>Anti-Depression</td>
<td>Cymbalta</td>
<td>3,000</td>
</tr>
<tr>
<td>Eszopiclone Tabs</td>
<td>CNS</td>
<td>Lunesta</td>
<td>250</td>
</tr>
<tr>
<td>Rasagiline Mesylate Tabs</td>
<td>Anti-parkinsonian</td>
<td>Azilect</td>
<td>200</td>
</tr>
<tr>
<td>Memantine Tabs</td>
<td>Alzheimer’s</td>
<td>Namenda</td>
<td>1,200</td>
</tr>
<tr>
<td>Gemifloxacin Tabs</td>
<td>Anti-Infectives</td>
<td>Factive</td>
<td>30</td>
</tr>
</tbody>
</table>

Finished Dosage Forms: Regulatory Status

<table>
<thead>
<tr>
<th>By Geography</th>
<th>US</th>
<th>EU</th>
</tr>
</thead>
<tbody>
<tr>
<td>Approved</td>
<td>31</td>
<td>22</td>
</tr>
<tr>
<td>Pending Approval</td>
<td>12</td>
<td>8</td>
</tr>
<tr>
<td>NPNC</td>
<td>45</td>
<td>32</td>
</tr>
<tr>
<td>Cephs</td>
<td>43</td>
<td>30</td>
</tr>
</tbody>
</table>

Finished Dosage Forms: Products Under Development

<table>
<thead>
<tr>
<th>By Geography</th>
<th>By Product Segment</th>
</tr>
</thead>
<tbody>
<tr>
<td>US</td>
<td>NPNC 83 Cephs 32</td>
</tr>
<tr>
<td>EU</td>
<td>Penems/Penicillin 10</td>
</tr>
<tr>
<td>RoW77</td>
<td>Penems/Penicillin 10</td>
</tr>
</tbody>
</table>

Filings / Approvals as of December 2012
1. NPNC – Non-penicillin, Non-cephalosporin
Orchid has an NCE pipeline with drugs for a multitude of therapeutic areas in various stages of development.

Follows one of the following business models:
- Out-licensing of NCEs (early phase or proof-of-concept phase)
- Co-development of NCEs
- ‘FTE’ based or ‘Fee for Service’ based Projects

The NCE pipeline is backed by a strong Intellectual Property Management system:
- A total of 644 patent applications filed and 226 patents published

<table>
<thead>
<tr>
<th>Therapeutic Segment</th>
<th>Discovery</th>
<th>Early Pre-clinical</th>
<th>Late Pre-clinical</th>
<th>Regulatory Toxicology</th>
<th>Phase I Clinical</th>
<th>Phase II Clinical</th>
</tr>
</thead>
<tbody>
<tr>
<td>Diabetes</td>
<td>Tyrosine-TZD. Non-PPAR molecule</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>DPP IV Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Novel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inflammation</td>
<td>Th1 / Th2 Cytokine Synthase Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>PDE IV Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>TNF α Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oncology (Non-cytotoxic)</td>
<td>STAT 3 / IL-6 Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>HDAC Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Anti-infectives</td>
<td>Oxazolidinone</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Cephalosporin</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clotting Disorders</td>
<td>Oral Direct Thrombin Inhibitor</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Obesity</td>
<td>Novel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>CNS</td>
<td>Novel</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
# Strategy in Place To Achieve Next Growth Phase

## Focus on long term supply contracts, new product approvals and development of new product segments to be the key growth drivers in the short–medium term

### Existing Business
- Clear defined strategies for API / Oral FDF / CRAMS segment
- Focus on long term contracts with marquee clients
- Niche injectable API products with limited competition to continue driving revenue growth
  - API supplies to Hospira for ADD-Vantage vials
- Launch new ANDAs / Dossiers in regulated markets
  - Leverage existing filings/approvals and continue to build pipeline for future growth

### Inorganic Strategies
- Focus on developing front-end marketing outfits and growth through in-licensing of products
- Expand presence in the European and Japanese markets
- Seeking opportunities with multiple partners for in-licensing deals/expansion in specific geographies

### New Niche Initiatives
- Development of NPNC (non injectables) FDF products
  - Aggressive thrust in oral FDF products in US, domestic and other emerging markets
- 8 FTF products with a combined market size of US$ 8bn
- Develop new product segments
THANK YOU

For any information or clarifications, please visit www.orchidpharma.com

or call

Ch Ram, Head - Communication & Investor Relations

on +91 98400 11626 / ram@orchidpharma.com

© 2013 Orchid Chemicals & Pharmaceuticals Ltd., All Rights Reserved.

This material was used during an oral presentation; it is not a complete record of the discussion. This work may not be used, sold, transferred, adapted, abridged, copied or reproduced in whole or in part in any manner or form or in any media without the prior written consent. All product names and company names and logos mentioned herein are the trademarks or registered trademarks of their respective owners.